Dwayaja H. Nadkarni, Feng Wang, Wei Wang, Elizabeth R. Rayburn, Scharri J. Ezell, Srinivasan Murugesan, Sadanandan E. Velu and Ruiwen Zhang Pages 227 - 236 ( 10 )
The high mortality rate and lack of effective therapies make lung cancer an ideal target for novel therapeutic agents. The present study was designed to implement a novel chemical synthesis pathway and to determine the biological activities of synthetic makaluvamine analogs in human lung cancer. Seventeen compounds were synthesized and purified, and their chemical structures were elucidated on the basis of physicochemical constants and NMR spectra. Their in vitro activity was determined in human lung cancer cell lines. Based on initial screens, compound Ic was found to be the most potent, and was therefore used as a model for further studies in lung cancer cells. Ic induced both apoptosis and S-phase cell cycle arrest. Furthermore, it activated p53 and induced cleavage of PARP and caspases 8 and 9. Our preclinical data indicate that the makaluvamine analogs are potential therapeutic agents against lung cancer, providing a basis for further development of Ic (and perhaps other analogs) as a novel anti-cancer agent.
Makaluvamine, marine alkaloid, lung cancer, apoptosis
University of Alabama at Birmingham, Department of Pharmacology and Toxicology, 1670 University Blvd, 113 Volker Hall, Birmingham, AL 35294, USA.